These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background. Rojas EA; Corchete LA; Mateos MV; García-Sanz R; Misiewicz-Krzeminska I; Gutiérrez NC Blood Cancer J; 2019 Nov; 9(12):90. PubMed ID: 31748515 [TBL] [Abstract][Full Text] [Related]
3. Clinical and cytogenetic characteristics of primary and secondary plasma cell leukemia under the new IMWG definition criteria: a retrospective study. Guan J; Ma J; Chen B Hematology; 2023 Dec; 28(1):2254556. PubMed ID: 37732631 [TBL] [Abstract][Full Text] [Related]
4. Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns. Schinke C; Boyle EM; Ashby C; Wang Y; Lyzogubov V; Wardell C; Qu P; Hoering A; Deshpande S; Ryan K; Thanendrarajan S; Mohan M; Yarlagadda N; Khan M; Choudhury SR; Zangari M; van Rhee F; Davies F; Barlogie B; Morgan G; Walker BA Blood Cancer J; 2020 Jun; 10(6):70. PubMed ID: 32555163 [TBL] [Abstract][Full Text] [Related]
5. [Effect of Circulating Plasma Cells on the Prognosis of Patients with Multiple Myeloma]. Li F; Gao YJ; Li SS; Xi YY; Yang XW; Su YH Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1771-1779. PubMed ID: 38071059 [TBL] [Abstract][Full Text] [Related]
6. Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia. Lionetti M; Musto P; Di Martino MT; Fabris S; Agnelli L; Todoerti K; Tuana G; Mosca L; Gallo Cantafio ME; Grieco V; Bianchino G; D'Auria F; Statuto T; Mazzoccoli C; De Luca L; Petrucci MT; Offidani M; Di Raimondo F; Falcone A; Caravita T; Omede' P; Morabito F; Tassone P; Boccadoro M; Palumbo A; Neri A Clin Cancer Res; 2013 Jun; 19(12):3130-42. PubMed ID: 23613318 [TBL] [Abstract][Full Text] [Related]
7. Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients. An G; Qin X; Acharya C; Xu Y; Deng S; Shi L; Zang M; Sui W; Yi S; Li Z; Hao M; Feng X; Jin F; Zou D; Qi J; Zhao Y; Tai YT; Wang J; Qiu L Ann Hematol; 2015 Feb; 94(2):257-64. PubMed ID: 25231928 [TBL] [Abstract][Full Text] [Related]
8. Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome. Todoerti K; Agnelli L; Fabris S; Lionetti M; Tuana G; Mosca L; Lombardi L; Grieco V; Bianchino G; D'Auria F; Statuto T; Mazzoccoli C; De Luca L; Petrucci MT; Morabito F; Offidani M; Di Raimondo F; Falcone A; Omede' P; Tassone P; Boccadoro M; Palumbo A; Neri A; Musto P Clin Cancer Res; 2013 Jun; 19(12):3247-58. PubMed ID: 23599371 [TBL] [Abstract][Full Text] [Related]
9. Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia. Chang H; Qi X; Yeung J; Reece D; Xu W; Patterson B Leuk Res; 2009 Feb; 33(2):259-62. PubMed ID: 18676019 [TBL] [Abstract][Full Text] [Related]
10. How We Manage Newly Diagnosed Multiple Myeloma With Circulating Tumor Cells. van de Donk NWCJ J Clin Oncol; 2023 Mar; 41(7):1342-1349. PubMed ID: 36450104 [No Abstract] [Full Text] [Related]
11. [Advances in the Diagnosis and Therapy of Primary Plasma Cell Leukemia -Review]. Wang H; Li JY; Sun C; Zhou X Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1837-1841. PubMed ID: 29262927 [TBL] [Abstract][Full Text] [Related]
12. Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma. Lee Y; Yun J; Jeong D; Ryu S; Kwon SR; Yun H; Kim SM; Park JH; Lee DS Leuk Lymphoma; 2022 Feb; 63(2):385-394. PubMed ID: 34592901 [TBL] [Abstract][Full Text] [Related]
13. The clinical characteristics and prognosis of patients with primary plasma cell leukemia (pPCL) according to the new IMWG definition criteria. Yan W; Fan H; Xu J; Liu J; Li L; Du C; Deng S; Sui W; Hao M; Yi S; Zou D; Qiu L; Xu Y; An G Leuk Lymphoma; 2022 Dec; 63(12):2955-2964. PubMed ID: 35819882 [TBL] [Abstract][Full Text] [Related]
14. Causes of death in primary plasma cell leukemia differ from multiple myeloma: A STROBE-compliant descriptive study based on SEER database. Ge X; Meng W; Wang W; Ma H; Zhao S; Cui K Medicine (Baltimore); 2022 Jul; 101(29):e29578. PubMed ID: 35866755 [TBL] [Abstract][Full Text] [Related]
18. Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile. Hofste Op Bruinink D; Kuiper R; van Duin M; Cupedo T; van der Velden VHJ; Hoogenboezem R; van der Holt B; Beverloo HB; Valent ET; Vermeulen M; Gay F; Broijl A; Avet-Loiseau H; Munshi NC; Musto P; Moreau P; Zweegman S; van de Donk NWCJ; Sonneveld P J Clin Oncol; 2022 Sep; 40(27):3132-3150. PubMed ID: 35357885 [TBL] [Abstract][Full Text] [Related]
19. Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. Mina R; Joseph NS; Kaufman JL; Gupta VA; Heffner LT; Hofmeister CC; Boise LH; Dhodapkar MV; Gleason C; Nooka AK; Lonial S Cancer; 2019 Feb; 125(3):416-423. PubMed ID: 30332496 [TBL] [Abstract][Full Text] [Related]
20. Primary Plasma Cell Leukemia: Real-World Retrospective Study of 46 Patients From a Single-Center Study in China. Yu T; Xu Y; An G; Tai YT; Ho M; Li Z; Deng S; Zou D; Yu Z; Hao M; Anderson KC; Qiu L Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e652-e659. PubMed ID: 32624447 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]